Photochemical inactivation of pathogens in platelets and plasma: Five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety;Inactivation photochimique des pathogènes des plaquettes et du plasma: Cinq ans d'utilisation clinique de routine et d'hémovigilance. Vers un changement de paradigme de la sécurité en transfusion

Transfusion Clinique et Biologique

Volumn 18, Issue 2, 2011, Pages 53-61

  Cazenave, J P ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Amotosalen; Blood plasma; Blood platelets; Blood transfusion; Clinical trials; Hemovigilance; Intercept; Pathogen inactivation; Pathogens

Indexed keywords

AMOTOSALEN;

BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; DISEASE TRANSMISSION; ERYTHROCYTE CONCENTRATE; FRANCE; HUMAN; INFECTION CONTROL; PLASMA; SHORT SURVEY; THROMBOCYTE; ULTRAVIOLET A RADIATION;

BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CLINICAL TRIALS AS TOPIC; FRANCE; HUMANS; PHOTOCHEMISTRY; PHOTOSENSITIZING AGENTS; PLASMA; PLATELET TRANSFUSION; PSORALENS; SOCIETIES, MEDICAL; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 79954628172     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2011.02.023     Document Type: Short Survey

References (39)

1. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
2. Alter H.J. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008, 22:97-102.
3. Klein H.G., Glynn S.A., Ness P.M., Blajchman M.A. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009, 49:1262-1268.
4. Klein H.G., Anderson D., Bernardi M.J., Carey W., Hoch J.S., Robitaille N., et al. Pathogen inactivation: making decisions about new technologies-Preliminary report of a consensus conference. Vox Sang 2007, 93:179-182.
5. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
6. Benjamin R.J., McCullough J., Mintz P.D., Snyder E., Sponitz W.D., Rizzo R.J., et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005, 45:1739-1749.
7. Mufti N.A., Erickson A.C., North A.K., Hanson D., Sawyer L., Corash L.M., et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010, 38:14-19.
8. Cazenave J.P. Inactivation des agents pathogènes dans les produits sanguins labiles: sécurité transfusionnelle et impact économique. Bull Acad Natl Med 2006, 190:169-188.
9. Naegelen C., Isola H., Dernis D., Maurel J.P., Tardivel R., Bois S., et al. Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP. Transf Clin Biol 2009, 16:179-189.
10. Stramer S.L., Hollinger E.B., Katz L.M., Kleinmann S., Metzel P.S., Gregory K.R., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49Suppl2:1S-29S.
11. Grass J.A., Hei D.J., Metchette K., Cimino G.D., Wiesehahn G.P., Corash L., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998, 91:2180-2188.
12. Corash L., Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004, 33:1-7.
13. Alter H.J., Houghton M. Hepatitis C virus and eliminating post-transfusion hepatitis. Nature Med 2000, 6:12-16.
14. Zappa A., Amendola A., Romano L., Zanetti A. Emerging and re-emerging viruses in the era of globalisation. Blood Transfus 2009, 7:167-171.
15. Heneine W., Kuehnert M.J. Preserving blood safety against emerging retroviruses. Transfusion 2006, 46:1276-1278.
16. Pozzetto B., Berthelot P. Virus émergents et ré-émergents et nouveaux risqué nosocomiaux. Hygienes 2008, 16:1-11.
17. XMRV: virus en quête d'une maladie ou nouveau virus qui cause le cancer de la prostate et/ou le syndrome de fatigue chronique ?. Papier Mauve 2010, 15:1-7. Centre de collaboration national des maladies infectieuses du Canada (CCNMI).
18. Katz L.M., Dodd R.Y. Human herpesvirus-8: what (not) to do redux?. Transfusion 2010, 50:959-962.
19. Forland F, Jansen A, de Carvalho Gomes H, Nokleby H, Escriva AB, Coulombier B, et al. Risk assessement on Q fever. European Centre for Disease Prevention and Control 2010; doi:10.2900/28860.
20. Charrel R.N., de Lamballerie X., Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007, 22:769-771.
21. Petersen L.R., Busch M.P. Transfusion-transmitted arboviruses. Vox Sang 2010, 98:495-503.
22. Gallian P., de Lamballerie X., de Micco P., Andreu G. Le virus West Nile: généralités et implications en transfusion sanguine. Transfus Clin Biol 2005, 12:11-17.
23. Rasongles P., Angelini-Tibert M.F., Simon P., Currie C., Isola H., Kientz D., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009, 49:1083-1091.
24. Liumbruno G.M., Calteri D., Petropulacos K., Mattivi A., Po C., Macini P., et al. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 2008, 6:199-210.
25. Cazenave J.P., Waller C., Kientz D., Mendel I., Lin L., Jacquet M., et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010, 50:1210-1219.
26. van Rhenen D., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
27. Janetzko K., Cazenave J.P., Kluter H., Kientz D., Michel M., Beris P., et al. Therapeutic efficacy and safety of photochemically treated aphaeresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
28. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
29. Murphy S., Snyder E., Cable R., Slichter S.J., Strauss R.G., McCullough J., et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006, 46:4624-4633.
30. Cazenave J.P., Isola H., Waller C., Kientz D. France: Intercept platelets and plasma. Pathogen inactivation: the penultimate paradigm shift 2010, 189-206. AABB Press, Bethesda, MD. J.P. AuBuchon, C.V. Prowse (Eds.).
31. Cazenave J.P., Waller C., Mendel I., Kientz D., Kandel G., Raidot J.P., et al. Clinical experience with pathogen inactivation of platelet components for transfusion support. Progress and challenges in transfusion medicine, hemostasis and hemotherapy. State of art 2008 2008, 248-263. Karger, Baden, Germany. R.E. Scharf (Ed.).
32. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3 year period. Transfusion 2010;51:622-9.
33. Osselaer J.C., Doyen C., Defoin L., Debry C., Goffaux M., Messe N., et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009, 49:1412-1422.
34. Cazenave J.P., Wiesel M.L., Mendel I., Faradji A., Mangin S., Perricard B., et al. Intensive and successful transfusion of pathogen inactivated Intercept® platelet concentrates for major gynecological and obstetrical surgery in Glanzmann thrombasthenia type 1 with the Gypsy mutation. Vox Sang 2008, 95:306.
35. Osselaer J.C., Cazenave J.P., Lambermont M., Garraud O., Hidajat M., Barbolla L., et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008, 94:315-323.
36. Kerkhoffs J.L., van Putten W.L., Novotny V.M., Te Boekhorst P.A., Schipperus M.R., Zwaginga J.J., et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010, 150:209-217.
37. Corash L, Sherman CD. Evaluation of platelet transfusion clinical trials. Br J Haematol 2011, doi:10.1111/j.1365-2141.2010.08413.
38. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, et al. A multi-center study of therapeutic efficacy and safety of platelet components treated with amotosalen and UVA pathogen inactivation stored for six or seven days prior to transfusion. Br J Haematol 2011; doi:10.1111/j.1365-2141.2011.
39. Miller FG, Joffe S. Equipoise and the dilemna of randomized clinical trials. N Engl J Med. 2011;364:476-80.